Novo Nordisk's growth momentum has decelerated sharply, with revenue growth falling to 2.1% in 2026Q2 from 24.0% in 2026Q1, while gross margin contracted to 78.2% from 86.0%, suggesting intensifying competitive pressure and potential pricing concessions. The c...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth decelerated to 2.1% in 2026Q2 from 24.0% in 2026Q1, while gross margin dipped to 78.2% from 86.0%, reflecting pricing pressure and product mix shifts.
Novo Nordisk is experiencing robust growth in its diabetes and obesity care segments, supported by strong Q1 results.
The company is delivering high capital returns to shareholders, enhancing investor appeal.
The Novo Nordisk Foundation's patient-capital structure provides a competitive moat, enabling long-term pipeline focus despite market volatility.
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 5, 2026 | $0.96+17.1% vs $0.82 | $12.1B+11.4% vs $10.9B |
Q2 2026 May 6, 2026 | $1.04+19.5% vs $0.87 | $11.0B+1.5% vs $10.9B |
Q1 2026 Feb 4, 2026 | $1.00+11.1% vs $0.90 | $12.5B+3.1% vs $12.1B |
Q1 2026 Feb 3, 2026 | $1.00+11.1% vs $0.90 | $12.5B+3.1% vs $12.1B |
Novo Nordisk is in the middle of an important product launch, as it rolls out a pill version of its GLP-1 drug. The company hopes to regain lost market share in the still-emerging GLP-1 weight-loss space from its key rival, Eli Lilly.
NVO's CagriSema delivers greater weight loss than Eli Lilly's tirzepatide in T2D and 21% weight loss in obesity, strengthening its late-stage pipeline.
Weight-loss pills could capture as much as half of the global obesity drug market by 2030, Novo Nordisk's chief executive told Reuters on Tuesday, as the Danish drugmaker positions itself for a shift away from weekly injections.
Viking Therapeutics and Roche are developing drugs for obesity and diabetes to challenge Eli Lilly and Novo Nordisk's market duopoly.
Benchmark NVO against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Novo Nordisk A/S (NVO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $39.40 | $174.96B | 11.15 | 6.43% | 33.14% | 60.7% | 4.53% | |
| $1170.48 | $1.1T | 51.00 | 44.7% | 33.53% | 92.53% | — | |
| $42.51 | $102.08B | 11.58 | 5.49% | 8.09% | 5.5% | — | |
| $168.37 | $130.49B | 12.87 | 8.63% | 17.02% | 21.72% | — | |
| $141.28 | $268.53B | 19.65 | 5.97% | 22.93% | 29.64% | — | |
| $137.96 | $2.46B | -41.06 | -2.33% | 3.78% | 2.61% | — |
Novo Nordisk A/S (NVO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when NVO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Novo Nordisk A/S (NVO) stock FAQ — growth, dividends, profitability & financials explained
Novo Nordisk A/S (NVO) reported $329.43B in revenue for fiscal year 2025. This represents a 2110% increase from $14.90B in 1996.
Novo Nordisk A/S (NVO) grew revenue by 6.4% over the past year. This is steady growth.
Yes, Novo Nordisk A/S (NVO) is profitable, generating $116.44B in net income for fiscal year 2025 (33.1% net margin).
Yes, Novo Nordisk A/S (NVO) pays a dividend with a yield of 4.53%. This makes it attractive for income-focused investors.
Novo Nordisk A/S (NVO) has a return on equity (ROE) of 60.7%. This is excellent, indicating efficient use of shareholder capital.
Novo Nordisk A/S (NVO) generated $48.92B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
